AURA
NASDAQAura Biosciences Inc.
Price$7.43+0.25 (+3.55%)
01:30 PM07:45 PM
News · 26 weeks57+1400%
2026-03-082026-08-30
Mix2890d
- Insider16(57%)
- SEC Filings9(32%)
- Other2(7%)
- Leadership1(4%)
Latest news
25 items- INSIDERChief People Officer Person Julie was granted 107,611 shares (SEC Form 4)4 - Aura Biosciences, Inc. (0001501796) (Issuer)
- INSIDERChief Reg. & Quality Officer Kratz Erica was granted 100,885 shares (SEC Form 4)4 - Aura Biosciences, Inc. (0001501796) (Issuer)
- INSIDERChief Medical Officer Hopkins Janet Jill was granted 58,850 shares, increasing direct ownership by 18% to 380,190 units (SEC Form 4)4 - Aura Biosciences, Inc. (0001501796) (Issuer)
- INSIDERSVP, Finance & PAO Elazzouzi Amy was granted 23,540 shares, increasing direct ownership by 20% to 143,600 units (SEC Form 4)4 - Aura Biosciences, Inc. (0001501796) (Issuer)
- INSIDERChief Operating Officer Abu-Absi Susan was granted 134,513 shares (SEC Form 4)4 - Aura Biosciences, Inc. (0001501796) (Issuer)
- SECSEC Form S-8 filed by Aura Biosciences Inc.S-8 - Aura Biosciences, Inc. (0001501796) (Filer)
- PRAura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA) ("Aura" or the "Company"), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that inducement equity awards (collectively, "Inducement Awards") were granted to Erica Kratz, Ph.D., Aura’s new Chief Regulatory and Quality Officer, Susan Abu-Absi, Ph.D., Aura’s new Chief Operating Officer, and Julie Person, Aura’s new Chief People Officer, each on September 1, 2026 (the "Grant Date"). The Inducement Awards were approved by the Compensation Committee of the Board of Directors of the Company in accordance with Nasdaq
- SECSEC Form EFFECT filed by Aura Biosciences Inc.EFFECT - Aura Biosciences, Inc. (0001501796) (Filer)
- INSIDERSEC Form 3 filed by new insider Person Julie3 - Aura Biosciences, Inc. (0001501796) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kratz Erica3 - Aura Biosciences, Inc. (0001501796) (Issuer)
- INSIDERSEC Form 3 filed by new insider Abu-Absi Susan3 - Aura Biosciences, Inc. (0001501796) (Issuer)
- SECSEC Form S-3 filed by Aura Biosciences Inc.S-3 - Aura Biosciences, Inc. (0001501796) (Filer)
- SECSEC Form 10-Q filed by Aura Biosciences Inc.10-Q - Aura Biosciences, Inc. (0001501796) (Filer)
- SECAura Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Leadership Update, Other Events, Financial Statements and Exhibits8-K - Aura Biosciences, Inc. (0001501796) (Filer)
- PRAura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business HighlightsPhase 3 CoMpass trial fully enrolled with 108 patients, exceeding enrollment target; on track for topline data in 2H 2027 Strategic operating plan refined to focus on development of bel-sar in ocular oncology Interim NMIBC data reinforce bel-sar’s potential for durable efficacy and favorable safety profile; NMIBC program being strategically deprioritized to focus company resources on ocular oncology Organizational restructuring and disciplined capital allocation strategy to align with ocular oncology focus extend expected cash runway into 1H 2029 Strengthening leadership team with appointments of experienced industry executives as Chief Operating Officer, Chief Regulatory and Quality Of
- SECAura Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Aura Biosciences, Inc. (0001501796) (Filer)
- INSIDERDirector Bender Jeremy was granted 30,000 shares (SEC Form 4)4 - Aura Biosciences, Inc. (0001501796) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bender Jeremy3 - Aura Biosciences, Inc. (0001501796) (Issuer)
- SECAura Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Aura Biosciences, Inc. (0001501796) (Filer)
- PRAura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of DirectorsBOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Jeremy Bender, Ph.D., M.B.A., to its Board of Directors. "I am thrilled to welcome Jeremy to our Board of Directors and excited to be working alongside him again," said Natalie Holles, Chief Executive Officer of Aura Biosciences. "Jeremy is an accomplished biotechnology leader with deep experience advancing innovative therapies through late-stage development, commercialization and significant value creation in rare oncology. As Aura advances toward poten
- INSIDEROfficer Kilroy Conor was granted 14,858 shares, increasing direct ownership by 7% to 232,693 units (SEC Form 4)4 - Aura Biosciences, Inc. (0001501796) (Issuer)
- SECSEC Form DEF 14A filed by Aura Biosciences Inc.DEF 14A - Aura Biosciences, Inc. (0001501796) (Filer)
- SECSEC Form PRE 14A filed by Aura Biosciences Inc.PRE 14A - Aura Biosciences, Inc. (0001501796) (Filer)
- INSIDEROfficer Gibney Anthony S sold $82,330 worth of shares (12,824 units at $6.42), decreasing direct ownership by 5% to 265,354 units (SEC Form 4) to cover withholding tax4 - Aura Biosciences, Inc. (0001501796) (Issuer)
- INSIDERDirector Srivastava Sapna was granted 15,000 shares, increasing direct ownership by 64% to 38,500 units (SEC Form 4)4 - Aura Biosciences, Inc. (0001501796) (Issuer)
AURA FAQ
7 questionsWhat does Aura Biosciences Inc. do?
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform to treat tumors of high unmet need in ocular and urologic oncology. Its AU-011, a VDC candidate, is being developed for the first line treatment of primary choroidal melanoma, a rare disease with no drugs approved. The company also develops AU-011 in additional ocular oncology indications, including choroidal metastases. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.Where does AURA stock trade?
Aura Biosciences Inc. (AURA) is listed on NASDAQ.What sector and industry is AURA in?
Aura Biosciences Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Aura Biosciences Inc. go public?
Aura Biosciences Inc. (AURA) completed its IPO in 2021.What are analysts saying about AURA?
Aura Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Evercore ISI: Outperform with a $1300.00 price target on 2025-11-26. Recent price targets range from $1300.00 to $4000.00.What companies are similar to AURA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), MRNA (Moderna Inc.), RVMD (Revolution Medicines Inc.). Compare AURA side-by-side with any of them on Quantisnow.How can I track AURA on Quantisnow?
Quantisnow aggregates Aura Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AURA to receive live email and push alerts on every new disclosure.